Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF POSITIVE CLINICAL DATA FROM PHASE 1 STUDY OF FS222 (CD137/PD-L1) AT THE 2024 ASCO2024.06.05
-
RETIREMENT OF EXECUTIVE DIRECTOR2024.06.05
-
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS2024.06.05
-
ADJUSTMENT TO CONVERSION PRICE OF THE BONDS2024.06.05
-
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 5 JUNE 20242024.06.05
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 20242024.06.03
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA2024.05.23
-
NEXT DAY DISCLOSURE RETURN2024.05.17